SPI Infoamtion

Table of Contents

1. Executive Summary
1.1 Prospects for India's Pharmaceutical Market
1.2 Aims, Scope and Format of the Report
1.3 Research Methods

2. The Indian Pharmaceutical Market
2.1 The Global Market: An Overview
2.2 Indian Market: $7.6bn Opportunity
2.3 Global Market Performances
2.3.1 US Market Expected to Contract in 2010.
2.3.2 Growth in EU and Japan will also Decelerate
2.3.3 Rapid Expansion in Emerging Markets
2.4 Key Trends in Global Market
2.4.1 M&A between Innovator & Generic Companies
2.4.2 Emerging Markets will Drive the Growth
2.4.3 The Future is an Increasingly Generic World
2.4.4 Greater Pressure on Cost & Price Reduction
2.5 The Trends in Indian Pharmaceutical Industry

3. Analysis of the Indian Pharmaceutical Market
3.1 A Rapidly Expanding Pharmaceutical Market
3.2 Pharmaceutical Market Analysis
3.3 Estimated Value for Prescription Market
3.4 Estimated Value for OTC Market
3.5 Estimated Market Volume for Generics
3.6 Branded Products Will Take Significant Market Share from 2009 to 2024
3.7 Major Selling Therapeutics Areas
3.7.1 Sales Figure for Major Therapeutics Areas
3.8 Forecasts for Major Therapeutics Market: Anti-Infective Medicines
3.8.1 Cephalosporins
3.8.2 Broad Spectrum Penicillins
3.8.3 Fluoroquinolones
3.8.4 Macrolides and Similar Types
3.9 Forecasts for Major Therapeutics Other than Anti-Infectives
3.9.1 Antiulcerants
3.9.2 Anti-rheumatics, Non-steroidal
3.9.3 Haematinics, Iron and All Combinations
3.9.4 Anti-epileptics
3.9.5 Antitussives
3.9.6 Multivitamins with Minerals
3.9.7 Biguanide Antidiabetics
3.10 Fastest Growing Classes in Indian Therapeutic Market

4. Key players in the Indian Pharmaceutical Industry
4.1 Introduction
4.2 The Chemical, Industrial & Pharmaceutical Laboratories (Cipla)
4.2.1 An Overview
4.2.2 Global Presence
4.2.3 Business Interests
4.2.4 Products
4.2.5 Revenue & Growth
4.3 Ranbaxy Laboratories
4.3.1 An Overview
4.3.2 Global Presence
4.3.3 Business Interests
4.3.4 Revenue & Growth
4.3.5 Therapeutic Focus Areas
4.3.6 Capabilities
4.3.7 Future Outlook
4.4 Piramal Healthcare
4.4.1 An Overview
4.4.2 Piramal's Corporate Restructuring
4.4.3 Therapeutic Interests
4.4.4 Global Presence
4.4.5 Strengths & Capabilities
4.4.6 Revenues & Growth
4.5 Zydus Cadila
4.5.1 An Overview
4.5.2 Global Presence
4.5.3 Business Functions
4.5.4 Capabilities
4.5.5 R&D
4.5.6 Focus Therapeutic Segments
4.5.7 Revenue & Growth
4.5.8 Future Outlook
4.6 Dr. Reddy's Laboratories
4.6.1 An Overview
4.6.2 Global Presence
4.6.3 Business Interests
4.6.4 Revenue & Growth
4.6.5 Capabilities
4.6.6 Future Outlook
4.7 Daiichi Sankyo
4.7.1 An Overview
4.7.2 Global Presence
4.7.3 Business Functions
4.7.4 Focus Therapeutic Segments
4.7.5 Revenue & Growth
4.7.6 Future Outlook
4.8 GlaxoSmithKline
4.8.1 An Overview
4.8.2 Therapeutic Areas
4.8.3 Revenue & Growth
4.8.4 Research & Development
4.8.5 Future Outlook
4.9 Abbott India Ltd
4.9.1 An Overview
4.9.2 Key Market Segments & Products
4.9.3 Revenues & Growth
4.10 Pfizer
4.10.1 An Overview
4.10.2 Products & Market Segment
4.10.3 Revenues & Growth
4.10.4 Pfizer's Academic and Other Contributions

5. Regulatory Policy and Framework
5.1 Introduction
5.2 Intellectual Property: an Overview
5.2.1 A Brief Look at the Indian Patents Act, 1970.
5.2.2 India's Membership of IPR Organisations
5.2.3 Compulsory Licenses and Foreign Technologies
5.2.4 Background to the WTO and TRIPS
5.2.5 Before TRIPS Lack of Patent Protection was Rife in Developing Nations
5.2.6 Main Issues Addressed in IP Law
5.2.7 Summary of Key Points from the IPR
5.3 Regulatory Framework for the Pharma Industry
5.3.1 India's Pricing Pattern for the Pharmaceutical Industry
5.3.2 National Pharmaceutical Pricing Authority (NPPA)
5.3.3 Drugs Price Control Order (DPCO), 1995
5.3.4 Understanding India's Regulatory Environment
5.3.5 Central Government Responsibilities
5.3.6 State Government Responsibilities
5.3.7 A National Drug Authority (NDA) to be Formed
5.3.8 Central Drugs Standard Control Organisation (CDSCO)
5.3.9 The Drugs Controller General of India (DCGI)
5.3.10 Good Manufacturing Practice (GMP) Compliance
5.4 Mashelkar Committee on Reviewing Pharmaceutical Policy
5.5 2009: The National Pharmaceutical Policy is Under Review
5.6 Budget 2008-09: Perspective of the Pharma Industry

6. Qualitative Analysis of the Indian Pharmaceutical Market
6.1 An Overview
6.2 Drivers in the Indian market
6.2.1 India has a Large Untapped Market
6.2.2 Growing Middle Class is Driving Growth.
6.2.3 Large Base of Skilled Workforce
6.2.4 Cost-effective Manufacturing & Chemical Synthesis
6.2.5 Government Incentives and Tax Relief
6.3 Restraints in the Indian Market
6.3.1 Price Regulations
6.3.2 Low Penetrated Market
6.3.3 Fragmented Industry
6.4 Emerging Trends and Opportunities in the Indian Market
6.4.1 Product Development & Innovation
6.4.2 Drug Patent Expiries
6.4.3 Greater Penetration of Health Insurance
6.4.4 Outsourcing Hub for Contract Manufacturing
6.5 Challenges Facing Indian Pharmaceutical Industry
6.5.1 IP & Patents: Incremental Innovation has Become a Point of Concern
6.5.2 The Bolar Provision Concerns Foreign MNCs
6.5.3 Emerging Competition from China and Other Economies
6.6 Porter's Five Forces Analysis of the Sector
6.6.1 Industry Competition
6.6.2 Bargaining Power of Buyers
6.6.3 Bargaining Power of Suppliers
6.6.4 Barriers to Entry
6.6.5 Threat of Substitutes
6.7 Objective Analysis.
6.7.1 Analysis: An Overview
6.7.2 Steps to Strengthen the Industry
6.8 Competition from Other Economies
6.8.1 China
6.9 Conclusion

7. Visiongain Interviews with Experts on the Indian Sector
7.1 Firsthand Interview for Expert Opinion 1
7.1.1 Challenges Facing Indian Industry
7.1.2 Will India be in the Top Five Largest Markets by 2020?
7.1.3 The Growing Problem of Counterfeit Drugs
7.1.4 The Pricing Structure and Prospects in the Future
7.1.5 The Growth in Sales of Patent and Generic Drugs by 2020
7.1.6 The Future Healthcare Coverage and Per Capita Spending
7.1.7 The Distribution System
7.1.8 Indian Government Support for Pharma & Biotech Industry
7.1.9 Potential of Indian Biotech Sector & Niche Areas
7.1.10 Networks in Indian Pharma & Biotech Industry
7.1.11 Manufacturing Competiveness
7.1.12 Treatments with Greatest Potential (2020) Relative to Price Increases
7.1.13 Therapeutic Areas with Greatest Potential (2009-2020)
7.2 Firsthand Interview for Expert Opinion 2
7.2.1 Bureaucratic Challenges
7.2.2 Improving Access to Rural Areas
7.2.3 Therapeutic Areas Requiring Increased Attention (2009-2024)
7.2.4 Antibiotics, Drug Resistance and Unmet Needs
7.3 Firsthand Interview for Expert Opinion 3
7.3.1 India's Key Strengths
7.3.2 India's Edge over China in Pharmaceutical Business
7.3.3 Need for Routine Inspection of Outsourcing Sites
7.3.4 Need for Creation of Economic Zone for Pharmaceutical Industry
7.3.5 Business Approach Needed for Rural Mass
7.3.6 India as an Emerging Market
7.3.7 Growth of India's Medical Tourism
7.3.8 Tropical Diseases Widespread in India
7.3.9 Vertical Integration Recommended for India's Companies
7.3.10 India's Emergence as a Major Pharmaceutical Market

8. Conclusions
8.1 Future Trends for Indian Pharma Industry
8.1.1 Greater Generic Penetration will Benefit Indian Producers
8.1.2 Biotechnology
8.1.3 Outsourcing and CRAMS
8.2 Looking to Developed Markets for Expansion
8.3 M&A are the Emerging Trend for Pharmaceutical Industry
8.4 Increasing Competition from China and Other Asian Countries
8.5 Measures to Increase Competitiveness of Indian Pharmaceutical Industry
8.5.1 Greater Investment into R&D
8.5.2 Academic-Industrial Partnership Model Should be Explored
8.5.3 India Should Exploit its Traditional Knowledge in Herbal Medicines
8.6 Future Outlook

List of Tables
Table 2.1 Pharmaceutical Sales ($bn) of World Top 20 Nations, 2008
Table 2.2 The Top 5 Nations with the Largest Populations in the World, 2009
Table 2.3 Real GDP Growth Rates (%) for Leading Pharmaceutical Countries, 2006-2009
Table 3.1 India's Total Pharmaceutical Sales ($m), 2008-2014
Table 3.2 India's Total Pharmaceutical Sales ($m), 2015-2024
Table 3.3 Long Range Forecasts for Indian Pharma Market, 2008, 2013, 2018 & 2024
Table 3.4 CAGR (%) for Pharmaceutical Sales in India & the Total World Market, 2008-2024
Table 3.5 Prescription Market ($m), 2008-2015
Table 3.6 Prescription Market ($m), 2016-2024
Table 3.7 OTC & Prescription-Only Pharmaceutical Markets, 2008
Table 3.8 Major OTC Categories in the Indian Market, 2008
Table 3.9 Points of Sales for OTCs in the Indian Market, 2008
Table 3.10 India's International Market for OTC Drug Sales ($m), 2008-2014
Table 3.11 India's International Market for OTC Drug Sales ($m), 2015-2024
Table 3.12 Indian National Market for OTC drugs, 2008-2015
Table 3.13 Indian National Market for OTC drugs, 2016-2024
Table 3.14 Major Drugs with Patent Expiry from 2009 to 2012
Table 3.15 Type of Counterfeit Drugs on the Worldwide Market
Table 3.16 Sales ($m) of Leading Anti-infectives in the Indian Market, 2007-08 & 2008-9
Table 3.17 Sales ($m) of Leading Therapeutic Areas other than Anti-infectives in the Indian Market, 2007-8 & 2008-9
Table 3.18 Forecasts for Cephalosporins Sales ($m), 2008-2015
Table 3.19 Forecasts for Cephalosporins Sales ($m) from 2016-2024
Table 3.20 Forecasts for Broad Spectrum Penicillins Sales ($m) from 2008-2015
Table 3.21 Sales Forecasts ($m) for Broad Spectrum Penicillins from 2016-2024
Table 3.22 Forecasts for Fluoroquinolones Sales ($m) from 2008-2014
Table 3.23 Forecasts for Fluoroquinolones Sales ($m) from 2016-2024
Table 3.24 Forecasts for Macrolides and Similar Types ($m) from 2008-2015
Table 3.25 Forecasts for Macrolides and Similar Types ($m) from 2016-2024
Table 3.26 Forecasts for Antiulcerants ($m) from 2008-2015
Table 3.27 Forecasts for Antiulcerants ($m) from 2016-2024
Table 3.28 Forecasts for Anti-rheumatics, Non-steroidal from 2008-2015
Table 3.29 Forecasts for Anti-rheumatics (Non-steroidal) from 2016-2024
Table 3.30 Forecasts for Haematinics, Iron and all Combinations, 2008-2015
Table 3.31 Forecasts for Haematinics, Iron and all Combinations, 2016-2024
Table 3.32 Forecasts for Anti-epileptics from 2008-2015
Table 3.33 Forecasts for Anti-epileptics from 2016-2024
Table 3.34 Forecasts for Antitussives from 2008-2015
Table 3.35 Forecasts for Antitussives from 2016-2024
Table 3.36 Forecasts for Multivitamins with Minerals, 2008-2015
Table 3.37 Forecasts for Multivitamins with Minerals, 2016-2024
Table 3.38 Forecasts for Biguanide Antidiabetics, 2008-2015
Table 3.39 Forecasts for Biguanide Antidiabetics, 2016-2024
Table 3.40 Fastest Growing Therapy Classes in India, 12 Months to Q1 2009/2008
Table 4.1 The Leading Corporate Groups in the Indian Pharmaceutical Market
Table 4.2 The Leading Players in the Indian Market, 2009
Table 4.3 Fastest Growing Local Companies from Top 50 in India
Table 4.4 Cipla's Worldwide Sales and Leading Markets, 2009
Table 4.5 Sales of Cipla's Leading Products by Therapeutic Class, 12 Months to Q1 2009
Table 4.6 Selected List of New Drugs Launched by Cipla Worldwide in 2008-2009
Table 4.7 Cipla's Global Product Registration 2008-09
Table 4.8 Piramal Healthcare - Top Selling Products, 12 Months to Q1 2009
Table 4.9 Zydus Cadila's Sales by Therapeutic Class in the Indian Market
Table 4.10 Zydus Cadila's Sale Figures for Leading Countries, 2009
Table 4.11 Zydus Cadila - Sales by Region, 12 Months to Q1 2009
Table 4.12 Zydus Cadila - Pipeline Products by Phase, 2009
Table 4.13 Dr. Reddy's Revenues from the Top 10 Brands in India, 2008-09
Table 4.14 Daiichi Sankyo - Top Selling Products, 12 Months to Q1 2009
Table 4.15 Daiichi Sankyo Product Pipeline by Phase, 2009
Table 4.16 GlaxoSmithKline - Top Selling Products, 2009
Table 4.17 Pfizer - Top Selling Products, 2009
Table 5.1 Indian Membership of International IPR Organisations
Table 6.1 SWOT Analysis for India's Pharmaceutical Sector: Strengths
Table 6.2 SWOT Analysis for India's Pharmaceutical Sector: Weaknesses
Table 6.3 SWOT Analysis for India's Pharmaceutical Sector: Opportunities
Table 6.4 SWOT Analysis for India's Pharmaceutical Sector: Threats

Lists of Figures
Figure 2.1 Worldwide Pharmaceutical Market, 2008
Figure 2.2 World Market Share for Top 20 Pharmaceutical Nations, 2007
Figure 2.3 Average Growth by Real GDP: 'Chindia' has the Highest Growth, 2006-2009
Figure 3.1 India's Total Pharmaceutical Sales ($m), 2008-2014
Figure 3.2 India's Total Pharmaceutical Sales ($m), 2015-2024
Figure 3.3 CAGR (%) for Pharmaceutical Sales in India and the Total World Market, 2008-2023.
Figure 3.4 Indian Domestic and International Market Share, 2006
Figure 3.5 Prescription Market ($m), 2008-2015
Figure 3.6 Prescription Market ($m), 2016-2024
Figure 3.7 Global Sales for OTC and Prescription-Only Pharmaceuticals, 2008
Figure 3.8 Major Categories for Sales of OTCs in the Indian Market, 2008
Figure 3.9 Points of Sales for OTCs in the Indian Market, 2008
Figure 3.10 India's International Market for OTC Drug Sales ($m) 2008-2024
Figure 3.11 Indian National Market for OTC Drugs, 2008-2024
Figure 3.12 Indian Share of the Global Generic Market by Volume, 2008
Figure 3.13 Forecast for India's Share of the Global Generic Market by Volume in 2024
Figure 3.14 Ratio of Patent and Generic Market Share in India by Value, 2008
Figure 3.15 Visiongain Forecast for Ratio of Patent and Generic Market Share in India by Value, 2024
Figure 3.16 Sales ($m) for the Leading Anti-infectives in the Indian Market, 2007-8 & 2008-9
Figure 3.17 Leading Therapeutic Areas Other than Anti-infectives in the Indian Market, 2007-8 & 2008-9
Figure 3.18 Cephalosporins Sales ($m) Forecast for 2008-2014
Figure 3.19 Cephalosporins Sales ($m) Forecast for 2015-2024
Figure 3.20 Forecasts for Broad Spectrum Penicillins 2008-2015
Figure 3.21 Forecasts for Broad Spectrum Penicillins 2016-2024
Figure 3.22 Forecasts for Fluoroquinolones 2008-2015
Figure 3.23 Forecasts for Fluoroquinolones 2016-2024
Figure 3.24 Forecasts for Macrolides and Similar Types, 2008-2015
Figure 3.25 Forecasts for Macrolides and Similar Types 2016-2024
Figure 3.26 Forecasts for Antiulcerants, 2008-2015
Figure 3.27 Forecasts for Antiulcerants, 2016-2024
Figure 3.28 Forecasts for Anti-rheumatics (Non-steroidal), 2008-2015
Figure 3.29 Forecasts for Anti-rheumatics (Non-steroidal), 2016-2024
Figure 3.30 Forecasts for Haematinics, Iron and all Combinations, 2008-2015
Figure 3.31 Forecasts for Haematinics, Iron and all Combinations, 2016-2024
Figure 3.32 Forecasts for Anti-epileptics 2008-2015
Figure 3.33 Forecasts for Anti-epileptics 2016-2024
Figure 3.34 Forecasts for Antitussives, 2008-2015
Figure 3.35 Forecasts for Antitussives, 2016-2024
Figure 3.36 Forecasts for Multivitamins with Minerals, 2008-2015
Figure 3.37 Forecasts for Multivitamins with Minerals, 2016-2024
Figure 3.38 Forecasts for Biguanide Antidiabetics, 2008-2015
Figure 3.39 Forecasts for Biguanide Antidiabetics, 2016-2024
Figure 3.40 Fastest Growing Therapy Classes in India; Fixed Rate Growth $(%), 12 Months to Q1 2009/2008
Figure 6.1 SWOT Analysis of the Indian Pharmaceutical Industry, 2009
Figure 8.1 Visiongain Model for Growth in the Indian Pharmaceutical Market, 2009-2024